INCY Incyte Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: INCY

Price (delayed)

$120.04

Market cap

$24.47B

P/E Ratio

57.44

Dividend/share

N/A

EPS

$2.09

Enterprise value

$21.22B

?
Relative Growth: Rel. Growth: 56
Relative Strength: Rel. Strength: 73
Relative Valuation: Rel. Valuation: 20
Relative Profitability: Rel. Profitability: 65

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of ...

Highlights
Incyte's revenue has increased by 25% YoY and by 3.3% from the previous quarter
INCY's gross profit is up by 25% year-on-year and by 3.4% since the previous quarter
INCY's P/E is 130% above its last 4 quarters average of 25.0 but 28% below its 5-year quarterly average of 80.0
The company's quick ratio rose by 24% YoY but it fell by 18% QoQ
INCY's net income has dropped by 75% since the previous quarter and by 66% year-on-year
INCY's EPS has shrunk by 74% QoQ and by 65% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.incyte.com
Peers: AMGN LGND PFE LLY

Key stats

What are the main financial stats of INCY

INCY stock price

How has the Incyte stock price performed over time
Intraday
-0.29%
1 week
5.94%
1 month
4.11%
1 year
28.41%
YTD
21.53%
QTD
-1.08%

Financial performance

How have Incyte's revenue and profit performed over time
Revenue
$6.01B
Gross profit
$5.57B
Operating income
$626.51M
Net income
$403.41M
Gross margin
92.7%
Net margin
6.7%
The net margin has dropped by 76% since the previous quarter and by 73% year-on-year
INCY's net income has dropped by 75% since the previous quarter and by 66% year-on-year
INCY's operating margin has dropped by 66% year-on-year and by 66% since the previous quarter
Incyte's operating income has plunged by 65% from the previous quarter and by 58% YoY

Price vs fundamentals

How does INCY's price correlate with its fundamentals

Growth

What is Incyte's growth rate over time

Valuation

What is Incyte stock price valuation
INCY P/E details
P/E
57.44
P/B
4.31
P/S
4.06
EV/EBIT
26.58
EV/EBITDA
23.66
EV/Sales
3.53
INCY's P/E is 130% above its last 4 quarters average of 25.0 but 28% below its 5-year quarterly average of 80.0
INCY's EPS has shrunk by 74% QoQ and by 65% YoY
INCY's equity is up by 21% year-on-year but it is down by 11% since the previous quarter
The stock's price to book (P/B) is 20% more than its 5-year quarterly average of 3.6 and 13% more than its last 4 quarters average of 3.8
Incyte's revenue has increased by 25% YoY and by 3.3% from the previous quarter
INCY's P/S is 7% above its last 4 quarters average of 3.8

Efficiency

How efficient is Incyte business performance
INCY's return on assets has dropped by 76% since the previous quarter and by 73% year-on-year
The ROE has plunged by 76% YoY and by 76% from the previous quarter
INCY's ROS has shrunk by 61% QoQ and by 60% YoY
The ROIC has plunged by 60% from the previous quarter and by 54% YoY

Dividends

What is INCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INCY.

Financial health

How did Incyte financials performed over time
The company's quick ratio rose by 24% YoY but it fell by 18% QoQ
The current ratio has grown by 20% YoY but it has contracted by 16% from the previous quarter
The debt is 99% smaller than the equity
INCY's equity is up by 21% year-on-year but it is down by 11% since the previous quarter
The debt is down by 10% year-on-year and by 2.8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.